Home » Topics » Regulatory » EMA

EMA
RSS

FDA and EMA accepts regulatory submissions of talazoparib for review

June 8, 2018

EMA grants PRIME designation for dilanubicel

June 7, 2018

EMA grants PRIME designation to AT-132 for the treatment of X-linked myotubular myopathy

June 6, 2018

Myalepta receives positive CHMP opinion for generalized and partial lipodystrophy

June 5, 2018

EMA committee backs approval of trastuzumab biosimilar Trazimera

June 4, 2018

EMA committee recommends approval of Translarna for younger children with DMD

June 4, 2018

EMA CHMP recommends approval of Sandoz adalimumab biosimilar

June 4, 2018

Aimovig receives positive CHMP opinion for the prevention of migraine

June 4, 2018

Exondys receives negative CHMP opinion

June 4, 2018

Tegsedi receives positive opinion in Europe

June 4, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
CINP 2026: Gut microbiota could predict antidepressant response
BioWorld
The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...
Ascending BCI systems deepen national security, ethical concerns
BioWorld
Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...
Deep brain stimulation from the shallows: tomorrow’s BCI technology?
BioWorld
Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...